Harmony Biosciences Holdings Inc. (HRMY) News
Filter HRMY News Items
HRMY News Results
|Loading, please wait...|
HRMY News Highlights
- HRMY's 30 day story count now stands at 5.
- Over the past 17 days, the trend for HRMY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about HRMY are RARE, STAR and TOP.
Latest HRMY News From Around the Web
Below are the latest news stories about HARMONY BIOSCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate HRMY as an investment opportunity.
Hot biotech stock leaders are surging within the IBD 50 elite list, with some passing buy points and others building bases. Catalyst now holds the top spot in the IBD 50 and leads an industry group of more than 800 companies. This biotech stock was Monday's IBD Stock Of The Day. It is also an IBD Tech Leader member and an IBD 50 Growth Stock to Watch.
Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Harmony Biosciences, Mobileye Global and Shoals Technologies are IPO stocks to buy and watch in today's stock market action.
Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Harmony Biosciences Holdings (HRMY - Research Report) today and set a price target of $70.00. The company's shares closed yesterday at $57.11.According to TipRanks, Suvannavejh is a 2-star analyst with an average return of -0.4% and a 47.01% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Axsome Therapeutics, and Harmony Biosciences Holdings.In addition to Mizuho Securities, Harmony Biosciences Holdings also received a Buy from Raymond James's Danielle Brill in a report issued on November 2. However, on November 1, Goldman Sachs maintained a Sell rating on Harmony Biosciences Holdings (NASDAQ: HRMY).
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) P/E Is Still On The Mark Following 34% Share Price Bounce
Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shareholders would be excited to see that the share price has had a...
In a report released today, Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings (HRMY - Research Report), with a price target of $60.00. The company's shares closed yesterday at $52.00.According to TipRanks, Fadia is an analyst with an average return of -1.0% and a 42.93% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Merus, Biogen, and Avadel Pharmaceuticals.Currently, the analyst consensus on Harmony Biosciences Holdings is a Strong Buy with an average price target of $61.14, which is a 17.58% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $60.
Harmony crushed third-quarter forecasts and unveiled promising results for its narcolepsy drug — leading the biotech stock to surge Tuesday.
At this time, I would like to welcome everyone to the Harmony Biosciences third quarter 2022 financial results conference call. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences third quarter 2022 financial results and provide a business update.
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?